Osteoporosis in Children and Young Adults: A Late Effect After Chemotherapy for Bone Sarcoma
- 474 Downloads
Premature bone loss after childhood chemotherapy may be underestimated in patients with bone sarcoma. Methotrexate (MTX), a standard agent in osteosarcoma protocols, reportedly reduces bone mineral density (BMD). The literature, however, has reported cases of BMD reduction in patients with Ewing's sarcoma treated without MTX. Thus, it is unclear whether osteoporosis after chemotherapy relates to MTX or to other factors.
We therefore asked whether (1) young patients with a bone sarcoma had BMD reduction, (2) patients treated with MTX had lower BMD, and (3) other factors (eg, lactose intolerance or vitamin D deficiency) posed additional risks for low BMD.
We retrospectively reviewed 43 patients with malignancies who had dual-energy x-ray absorptiometry (DEXA) (lumbar, femoral); 18 with Ewing's sarcoma (mean age, 26 ± 8 years), and 25 with an osteosarcoma (mean age, 27 ± 10 years). The mean time since diagnosis was 8 ± 4 years in the group with Ewing’s sarcoma and 7 ± 5 years in the group with osteosarcoma. At last followup we determined BMD (computing z-scores), fracture rate, and lifestyle, and performed serum analysis.
BMD reduction was present in 58% of patients (37% had a z-score between −1 and −2 SD, 21% had a z-score less than −2 SD) in at least one measured site. Seven of the 43 patients (16%) had nontrauma or tumor-associated fractures after chemotherapy. Findings were similar in the Ewing and osteosarcoma subgroups. We found vitamin D deficiency in 38 patients (88%) and borderline elevated bone metabolism; lactose intolerance was present in 16 patients (37%).
Doctors should be aware of the possibility of major bone loss after chemotherapy with a risk of pathologic fracture. Vitamin D deficiency, calcium malnutrition, and lactose intolerance may potentiate the negative effects of chemotherapy, and should be considered in long-term patient management.
Level of Evidence
Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.
KeywordsBone Mineral Density Osteoporosis Osteosarcoma Lower Bone Mineral Density Lactose Intolerance
We thank Franz Quehenberger PhD, Institute of Medical Informatics, Statistics and Documentation, for statistical analysis, and Thomas Lovse MD, Karin Novotny, and Andreas Frings for their assistance.
- 3.Berger DP, Engelbrecht R, Mertelsmann R. [The Red Book - Hämatology and Internistic Onkology] [in German]. Landsberg, Germany: Hüthig Jehle Rehm GmbH; 2006.Google Scholar
- 4.Bielack S, Kempf-Bielack B, Schwenzer D, Birkfellner T, Delling G, Ewerbeck V, Exner GU, Fuchs N, Göbel U, Graf N, Heise U, Helmke K, von Hochstetter AR, Jürgens H, Maas R, Münchow N, Salzer-Kuntschik M, Treuner J, Veltmann U, Werner M, Winkelmann W, Zoubek A, Kotz R. [Neoadjuvant therapy for localized osteosarcoma of extremities; results from the Cooperative Osteosarcoma study group COSS of 925 patients] [in German]. Klin Pädiatr. 1999;211:260–270.PubMedGoogle Scholar
- 5.Bob A, Bob K. [Internal Medicine] [in German]. Stuttgart, Germany: Thieme; 2009.Google Scholar
- 14.Herold G. [Internal Medicine] [in German]. Köln, Germany: Herold; 2008.Google Scholar
- 15.Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v204–v213.PubMedCrossRefGoogle Scholar
- 19.IARC, International Agency for Research on Cancer. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2002.Google Scholar
- 23.Kaste SC, Chesney RW, Hudson MM, Lustig RH, Rose SR, Carbone LD. Bone mineral status during and after therapy of childhood cancer: an increasing population with multiple risk factors for impaired bone health. (Comment on J Bone Miner Res. 2009;14:2002–2009). J Bone Miner Res. 1999;14:2010–2014.Google Scholar
- 27.Obermayer-Pietsch BM, Bonelli CM, Walter DE, Kuhn RJ, Fahrleitner-Pammer A, Berghold A, Goessler W, Stepan V, Dobnig H, Leb G, Renner W. Genetic predisposition for adult lactose intolerance and relation to diet, bone density, and bone fractures. J Bone Miner Res. 2004;19:42–47.PubMedCrossRefGoogle Scholar
- 31.Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H; European Intergroup Cooperative Ewing’s Sarcoma Study-92. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment: cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008;26:4385–4393.PubMedCrossRefGoogle Scholar